Medical - Pharmaceuticals
Compare Stocks
5 / 10Stock Comparison
LFMD vs HIMS vs TDOC vs DOCS vs AMWL
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Equipment & Services
Medical - Healthcare Information Services
Medical - Healthcare Information Services
Medical - Healthcare Information Services
LFMD vs HIMS vs TDOC vs DOCS vs AMWL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Pharmaceuticals | Medical - Equipment & Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Medical - Healthcare Information Services |
| Market Cap | $215M | $6.63B | $1.26B | $5.24B | $129M |
| Revenue (TTM) | $219M | $2.35B | $2.51B | $638M | $182M |
| Net Income (TTM) | $-17M | $128M | $-171M | $239M | $-88M |
| Gross Margin | 86.7% | 69.7% | 65.6% | 89.7% | 38.7% |
| Operating Margin | -5.9% | 4.6% | -7.6% | 37.4% | -50.6% |
| Forward P/E | — | 51.5x | — | 16.8x | — |
| Total Debt | $6M | $1.12B | $1.04B | $12M | $5M |
| Cash & Equiv. | $37M | $229M | $781M | $210M | $182M |
LFMD vs HIMS vs TDOC vs DOCS vs AMWL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| LifeMD, Inc. (LFMD) | 100 | 38.1 | -61.9% |
| Hims & Hers Health,… (HIMS) | 100 | 235.7 | +135.7% |
| Teladoc Health, Inc. (TDOC) | 100 | 4.2 | -95.8% |
| Doximity, Inc. (DOCS) | 100 | 44.7 | -55.3% |
| American Well Corpo… (AMWL) | 100 | 3.1 | -96.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LFMD vs HIMS vs TDOC vs DOCS vs AMWL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LFMD is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 220.7% 10Y total return vs HIMS's 161.9%
- 1.5% yield; the other 4 pay no meaningful dividend
HIMS ranks third and is worth considering specifically for growth exposure.
- Rev growth 59.0%, EPS growth -3.8%, 3Y rev CAGR 64.5%
- 59.0% revenue growth vs LFMD's -8.7%
Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.
DOCS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.03
- Lower volatility, beta 1.03, Low D/E 1.1%, current ratio 6.97x
- Beta 1.03, current ratio 6.97x
- Better valuation composite
AMWL is the clearest fit if your priority is momentum.
- +14.3% vs DOCS's -55.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 59.0% revenue growth vs LFMD's -8.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 37.5% margin vs AMWL's -48.2% | |
| Stability / Safety | Beta 1.03 vs HIMS's 2.40, lower leverage | |
| Dividends | 1.5% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +14.3% vs DOCS's -55.4% | |
| Efficiency (ROA) | 20.7% ROA vs AMWL's -25.1%, ROIC 20.0% vs -95.1% |
LFMD vs HIMS vs TDOC vs DOCS vs AMWL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
LFMD vs HIMS vs TDOC vs DOCS vs AMWL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 2 of 6 categories
TDOC leads 1 • LFMD leads 1 • HIMS leads 0 • AMWL leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TDOC is the larger business by revenue, generating $2.5B annually — 13.8x AMWL's $182M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, HIMS holds the edge at +28.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $219M | $2.3B | $2.5B | $638M | $182M |
| EBITDAEarnings before interest/tax | -$5M | $164M | $42M | $250M | -$59M |
| Net IncomeAfter-tax profit | -$17M | $128M | -$171M | $239M | -$88M |
| Free Cash FlowCash after capex | $15M | $73M | $251M | $314M | -$42M |
| Gross MarginGross profit ÷ Revenue | +86.7% | +69.7% | +65.6% | +89.7% | +38.7% |
| Operating MarginEBIT ÷ Revenue | -5.9% | +4.6% | -7.6% | +37.4% | -50.6% |
| Net MarginNet income ÷ Revenue | -7.8% | +5.5% | -6.8% | +37.5% | -48.2% |
| FCF MarginFCF ÷ Revenue | +6.8% | +3.1% | +10.0% | +49.2% | -22.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | +28.4% | -2.5% | +9.8% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -16.0% | -27.3% | +32.1% | -16.2% | +44.5% |
Valuation Metrics
TDOC leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 23.5x trailing earnings, DOCS trades at a 53% valuation discount to HIMS's 50.3x P/E. On an enterprise value basis, TDOC's 15.1x EV/EBITDA is more attractive than HIMS's 42.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $215M | $6.6B | $1.3B | $5.2B | $129M |
| Enterprise ValueMkt cap + debt − cash | $185M | $7.5B | $1.5B | $5.0B | -$48M |
| Trailing P/EPrice ÷ TTM EPS | -19.52x | 50.32x | -6.11x | 23.45x | -1.30x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 51.51x | — | 16.83x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.30x | — |
| EV / EBITDAEnterprise value multiple | — | 42.68x | 15.13x | 21.14x | — |
| Price / SalesMarket cap ÷ Revenue | 1.11x | 2.82x | 0.50x | 9.18x | 0.52x |
| Price / BookPrice ÷ Book value/share | 8.75x | 12.25x | 0.89x | 4.84x | 0.50x |
| Price / FCFMarket cap ÷ FCF | 33.61x | 89.61x | 4.40x | 19.64x | — |
Profitability & Efficiency
DOCS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
DOCS delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-162 for LFMD. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs HIMS's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -162.4% | +23.7% | -12.4% | +24.4% | -33.5% |
| ROA (TTM)Return on assets | -24.3% | +6.0% | -5.9% | +20.7% | -25.1% |
| ROICReturn on invested capital | — | +10.7% | -11.5% | +20.0% | -95.1% |
| ROCEReturn on capital employed | -37.4% | +10.9% | -10.0% | +22.3% | -36.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 6 | 9 | 6 |
| Debt / EquityFinancial leverage | 0.27x | 2.07x | 0.75x | 0.01x | 0.02x |
| Net DebtTotal debt minus cash | -$30M | $892M | $259M | -$197M | -$178M |
| Cash & Equiv.Liquid assets | $37M | $229M | $781M | $210M | $182M |
| Total DebtShort + long-term debt | $6M | $1.1B | $1.0B | $12M | $5M |
| Interest CoverageEBIT ÷ Interest expense | -6.48x | — | -8.76x | — | -239.18x |
Total Returns (Dividends Reinvested)
LFMD leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, AMWL leads with a +14.3% total return vs DOCS's -55.4%. The 3-year compound annual growth rate (CAGR) favors LFMD at 40.8% vs AMWL's -42.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +28.7% | -23.2% | -1.3% | -39.9% | +59.8% |
| 1-Year ReturnPast 12 months | -43.9% | -51.0% | +1.5% | -55.4% | +14.3% |
| 3-Year ReturnCumulative with dividends | +178.9% | +116.6% | -73.3% | -24.2% | -80.7% |
| 5-Year ReturnCumulative with dividends | -45.8% | +137.6% | -95.4% | -50.9% | -97.2% |
| 10-Year ReturnCumulative with dividends | +220.7% | +161.9% | -41.1% | -50.9% | -98.3% |
| CAGR (3Y)Annualised 3-year return | +40.8% | +29.4% | -35.6% | -8.8% | -42.2% |
Risk & Volatility
Evenly matched — DOCS and AMWL each lead in 1 of 2 comparable metrics.
Risk & Volatility
DOCS is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 84.7% from its 52-week high vs LFMD's 28.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.12x | 2.40x | 1.91x | 1.03x | 1.47x |
| 52-Week HighHighest price in past year | $15.84 | $70.43 | $9.77 | $76.51 | $9.15 |
| 52-Week LowLowest price in past year | $2.56 | $13.74 | $4.40 | $20.55 | $3.71 |
| % of 52W HighCurrent price vs 52-week peak | +28.3% | +36.4% | +71.2% | +34.0% | +84.7% |
| RSI (14)Momentum oscillator 0–100 | 70.8 | 54.5 | 74.1 | 60.1 | 67.1 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 34.9M | 5.5M | 2.7M | 59K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: LFMD as "Buy", HIMS as "Hold", TDOC as "Hold", DOCS as "Buy". Consensus price targets imply 89.3% upside for LFMD (target: $9) vs 8.9% for TDOC (target: $8). LFMD is the only dividend payer here at 1.53% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Hold | Buy | — |
| Price TargetConsensus 12-month target | $8.50 | $29.67 | $7.58 | $42.79 | — |
| # AnalystsCovering analysts | 10 | 19 | 42 | 22 | — |
| Dividend YieldAnnual dividend ÷ price | +1.5% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | — | — | — | — |
| Dividend / ShareAnnual DPS | $0.07 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.4% | 0.0% | +2.3% | +0.0% |
DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TDOC leads in 1 (Valuation Metrics). 1 tied.
LFMD vs HIMS vs TDOC vs DOCS vs AMWL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is LFMD or HIMS or TDOC or DOCS or AMWL a better buy right now?
For growth investors, Hims & Hers Health, Inc.
(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -8. 7% for LifeMD, Inc. (LFMD). Doximity, Inc. (DOCS) offers the better valuation at 23. 5x trailing P/E (16. 8x forward), making it the more compelling value choice. Analysts rate LifeMD, Inc. (LFMD) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — LFMD or HIMS or TDOC or DOCS or AMWL?
On trailing P/E, Doximity, Inc.
(DOCS) is the cheapest at 23. 5x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, Doximity, Inc. is actually cheaper at 16. 8x.
03Which is the better long-term investment — LFMD or HIMS or TDOC or DOCS or AMWL?
Over the past 5 years, Hims & Hers Health, Inc.
(HIMS) delivered a total return of +137. 6%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: LFMD returned +220. 7% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — LFMD or HIMS or TDOC or DOCS or AMWL?
By beta (market sensitivity over 5 years), Doximity, Inc.
(DOCS) is the lower-risk stock at 1. 03β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 134% more volatile than DOCS relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — LFMD or HIMS or TDOC or DOCS or AMWL?
By revenue growth (latest reported year), Hims & Hers Health, Inc.
(HIMS) is pulling ahead at 59. 0% versus -8. 7% for LifeMD, Inc. (LFMD). On earnings-per-share growth, the picture is similar: Teladoc Health, Inc. grew EPS 80. 6% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — LFMD or HIMS or TDOC or DOCS or AMWL?
Doximity, Inc.
(DOCS) is the more profitable company, earning 39. 1% net margin versus -38. 4% for American Well Corporation — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is LFMD or HIMS or TDOC or DOCS or AMWL more undervalued right now?
On forward earnings alone, Doximity, Inc.
(DOCS) trades at 16. 8x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 34. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LFMD: 89. 3% to $8. 50.
08Which pays a better dividend — LFMD or HIMS or TDOC or DOCS or AMWL?
In this comparison, LFMD (1.
5% yield) pays a dividend. HIMS, TDOC, DOCS, AMWL do not pay a meaningful dividend and should not be held primarily for income.
09Is LFMD or HIMS or TDOC or DOCS or AMWL better for a retirement portfolio?
For long-horizon retirement investors, Doximity, Inc.
(DOCS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03)). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DOCS: -50. 9%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between LFMD and HIMS and TDOC and DOCS and AMWL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LFMD is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; DOCS is a small-cap high-growth stock; AMWL is a small-cap quality compounder stock. LFMD pays a dividend while HIMS, TDOC, DOCS, AMWL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.